Aurora Spine Announces First Surgery Using Zip Graft(TM) Bone Dowel

CARLSBAD, CALIFORNIA--( July 25, 2014) - Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first U.S. surgery using the ZIP Graft ™ pre-packaged sterile bone dowel. The surgery was performed at Madison County Hospital in London, Ohio by Dr. Won Song.

The Aurora Zip Graft is a bone dowel designed specifically to fit into the ZIP™ MIS Interspinous Fusion System. "We are very excited to see the Zip Graft used in conjunction with the Zip MIS fusion device. The allograft bone dowels are designed and sized to fit into our devices thus creating an integrated fit every time" stated Doug Johnson VP of Sales, East.

NASDAQ Welcomes Intersect ENT (NASDAQ: XENT) to The NASDAQ Stock Market

NEW YORK, July 24, 2014 -- The NASDAQ OMX Group, Inc. (NDAQ) announced that trading of Intersect ENT (XENT), a commercial drug-device company, commenced on The NASDAQ Stock Market on July 24, 2014.

Intersect ENT, Inc. is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's drug-eluting bioabsorbable implant technology enables targeted and sustained release of therapeutic agents. Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved for use in patients with chronic sinusitis. Intersect ENT is developing new, less invasive and more cost-effective drug-eluting bioabsorbable treatment options for the management of chronic sinusitis in the physician office setting to provide benefits for patients, physicians and payors.

Intuitive Surgical Announces Second Quarter Earnings

SUNNYVALE, Calif., July 22, 2014-- Intuitive Surgical, Inc. (ISRG), the industry leader in robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2014.

Q2 Highlights

In the second quarter of 2014, worldwide procedures grew 9% over the second quarter of 2013, up 8% sequentially over the first quarter of 2014. The Company shipped 96 systems during the second quarter, compared with 87 systems shipped in the first quarter of 2014. In addition,

• The Company launched the da Vinci Xi system in the U.S. Fifty of the ninety-six systems shipped in the quarter were da Vinci Xi models.
• The Company entered into an agreement with its Japanese distributor to transition the business to a direct market in June.
• The Company's vessel sealer was cleared by the FDA for use with da Vinci Xi.
• The Company received FDA clearance of da Vinci SP 999 and commenced efforts to develop the product towards commercialization.

BioLife Solutions Announces Manufacturing Agreement With Somahlution LLC

Company to Produce DuraGraft® Tissue Preservation Solution for Storage of Harvested Veins

BOTHELL, Wash., July 17, 2014 -- BioLife Solutions, Inc. (NASDAQ:  BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced the execution of a long-term contract manufacturing services agreement with Somahlution LLC, a Jupiter, Florida-based biotechnology company.

Under the terms of the three-year agreement, BioLife will manufacture DuraGraft, a tissue preservation solution for storage of harvested veins used in coronary artery bypass graft (CABG) and other vascular access surgeries.  Unlike existing potentially cyotocidal and clinically-unproven solutions, DuraGraft is the first Endothelial Damage Inhibitor (EDI) that uniquely protects vascular endothelium and its associated architecture. Financial terms of the agreement were not disclosed.